RESUMEN
UNLABELLED: A meta-analysis of data primarily from PET oncologic investigations using FDG PET was performed. Its purpose was to establish statistical features of the distributions of standardized uptake values (SUVs) as possible aids in the diagnostic process. METHODS: We obtained 1536 values of oncologic markers from patient studies of 40 investigations in the literature. Statistical parameters were tabulated for analysis. RESULTS: A significant observation is that, unlike skewed SUV histograms, log10SUV has Gaussian behavior, which is not uncommon for biologic quantities. This was found for SUVs of FDG and 2 amino acids as well as a few other cancer markers. A possible model for explaining this is proposed. For FDG, the SD sigma of the log10SUVs for an average cancer category was 0.23. Examining data within the framework of the model points to physiologic factors as dominating SUV variability rather than PET protocols. When data for a single cancer category were available from multiple institutions, averages, mean(SUV)s, disagree beyond chance expectations. Diagnostic utility suggestions include a universal linear relationship between sensitivity and severity, defined as SUV/mean(SUV), on semilogarithmic probability paper; a generic receiver-operating-characteristic curve for all cancers; using [log10(mean(SUVmal)/mean(SUVnorm))] divided by (sigma(mal)2 + sigma(norm)2)(1/2) as a simple diagnostic effectiveness measure; and using Gaussian log10SUVs to avoid erroneous P values. CONCLUSION: Using the logarithms of markers, such as SUVs, several advantages stemming from their Gaussian nature can be achieved with benefits ensuing to the diagnostic process.
Asunto(s)
Fluorodesoxiglucosa F18 , Neoplasias/diagnóstico por imagen , Radiofármacos , Tomografía Computarizada de Emisión , Biomarcadores de Tumor , Fluorodesoxiglucosa F18/farmacocinética , Humanos , Curva ROC , Radiofármacos/farmacocinética , Tomografía Computarizada de Emisión/estadística & datos numéricosAsunto(s)
Radioisótopos de Carbono , Neoplasias Pulmonares/diagnóstico por imagen , Metionina , Tomografía Computarizada de Emisión , Humanos , Neoplasias Pulmonares/patología , Ganglios Linfáticos/diagnóstico por imagen , Metástasis Linfática , Estadificación de Neoplasias , Radiofármacos , Sensibilidad y Especificidad , Tomografía Computarizada por Rayos XRESUMEN
This retrospective study was done to evaluate the utility of 2-[F-18]fluoro-2-deoxy-D-glucose positron emission tomography (F-18-FDG PET) in identifying primary and recurrent breast cancer and lymph node metastases. One hundred whole-body PET scans of 87 patients were reviewed. PET results obtained with F-18-FDG and an ECAT/EXACT-921 or an ECAT-931 (Siemens/CTI) were based on visual interpretation, or standardized uptake values (SUVs), related to histology and also compared to computerized tomography (CT) and mammography results. The sensitivity for PET in detecting primary (N = 35 studies) and recurrent breast cancer (N = 65 studies) was 96% and 85% with a specificity of 91% and 73%. The sensitivity for lymph node metastases at the time of initial diagnosis was 100% with a specificity of 100%. Quantitative SUV information did not improve the accuracy of F-18-FDG PET in identifying primary breast cancers. The results suggest that whole-body PET is useful in detecting recurrence or metastases, may be useful in detecting lymph node metastases prior to initial axillary lymph node dissection, but is less sensitive in excluding axillary lymph nodes metastases later in the course of the disease.
RESUMEN
This study was done to determine whether 1-[(11)C]ACBC PET has any advantages over 2-[(18)F]FDG PET, CT, or MRI in detecting recurrent brain tumors, and whether quantitative 1-[(11)C]ACBC PET information improves the accuracy of "visual" image interpretation.Twenty patients with recurrent brain tumor underwent dynamic PET. Images were analyzed by visual interpretation; in addition, standardized uptake values (SUVs) and Patlak values (k(1)*k(3)/k) were evaluated.1-[(11)C]ACBC identified 19/20 recurrent brain tumors, [18F]FDG 13/19, MRI 13/19, and CT 8/16. Based on SUVs, the average tumor-to-contralateral gray matter ratio of 1-[(11)C]ACBC was 5.0 and 0.5 for 2-[(18)F]FDG. Mean Patlak values of 1-[(11)C]ACBC were 0.044 +/- 0.047 for high and 0.034 +/- 0.026 for low grade tumors. However, visual interpretation was effective without quantitative PET data.1-[(11)C]ACBC, accurately detects recurrent tumors for selecting biopsy sites and treatment planning.
RESUMEN
UNLABELLED: Boron neutron capture therapy (BNCT) using 4-[10B]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as currently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT. METHODS: We used PET to noninvasively obtain in vivo information on the pharmacokinetics of the 18F-labeled analog of BPA-Fr in two patients with glioblastoma multiforme. Time-activity curves generated from the bolus injection of 18F-BPA-Fr were coinvolved to simulate a continuous infusion used for BNCT therapy. RESULTS: Distribution of 18F-BPA-Fr by PET was found to be consistent with tumor as identified by MR imaging. The 18F-BPA-Fr tumor-to-normal brain uptake ratio was 1.9 in Patient 1 and 3.1 in Patient 2 at 52 min after injection. The 18F-BPA-Fr uptake ratio in glioblastoma paralleled that of nonlabeled BPA-Fr seen in patients as previously determined by boron analysis of human glioblastoma tissue obtained from pre-BNCT surgical biopsy. CONCLUSION: Knowledge of the biodistribution of BPA-Fr enables pre-BNCT calculation of expected tissue dosimetry for a selected dose of BPA-Fr at a specific neutron exposure. Fluorine-18-BPA-Fr PET is capable of providing in vivo BPA-Fr biodistribution data that may prove valuable for patient selection and pre-BNCT treatment planning.
Asunto(s)
Compuestos de Boro , Terapia por Captura de Neutrón de Boro , Neoplasias Encefálicas/diagnóstico por imagen , Radioisótopos de Flúor , Fructosa , Glioblastoma/diagnóstico por imagen , Fenilalanina/análogos & derivados , Fármacos Sensibilizantes a Radiaciones , Tomografía Computarizada de Emisión , Compuestos de Boro/farmacocinética , Neoplasias Encefálicas/radioterapia , Femenino , Radioisótopos de Flúor/uso terapéutico , Fructosa/farmacocinética , Glioblastoma/radioterapia , Humanos , Persona de Mediana Edad , Fenilalanina/farmacocinética , Fármacos Sensibilizantes a Radiaciones/farmacocinéticaRESUMEN
A simplified approach involving linear-regression straight-line parameter fitting of dynamic scan data is developed for both specific and nonspecific models. Where compartmental-model topologies apply, the measured activity may be expressed in terms of: its integrals, plasma activity and plasma integrals--all in a linear expression with macroparameters as coefficients. Multiple linear regression, as in spreadsheet software, determines parameters for best data fits. Positron emission tomography (PET)-acquired gray-matter images in a dynamic scan are analyzed: both by this method and by traditional iterative nonlinear least squares. Both patient and simulated data were used. Regression and traditional methods are in expected agreement. Monte-Carlo simulations evaluate parameter standard deviations, due to data noise, and much smaller noise-induced biases. Unique straight-line graphical displays permit visualizing data influences on various macroparameters as changes in slopes. Advantages of regression fitting are: simplicity, speed, ease of implementation in spreadsheet software, avoiding risks of convergence failures or false solutions in iterative least squares, and providing various visualizations of the uptake process by straight line graphical displays. Multiparameter model-independent analyses on lesser understood systems is also made possible.
Asunto(s)
Análisis de los Mínimos Cuadrados , Modelos Estadísticos , Tomografía Computarizada de Emisión , Algoritmos , Artefactos , Sesgo , Encéfalo/diagnóstico por imagen , Gráficos por Computador , Simulación por Computador , Desoxiglucosa/análogos & derivados , Femenino , Radioisótopos de Flúor , Fluorodesoxiglucosa F18 , Humanos , Procesamiento de Imagen Asistido por Computador/estadística & datos numéricos , Modelos Lineales , Método de Montecarlo , Trastornos Psicóticos/diagnóstico por imagen , Radiofármacos , Programas Informáticos/estadística & datos numéricos , Tomografía Computarizada de Emisión/estadística & datos numéricosRESUMEN
UNLABELLED: Fluorine-18 labeled deoxyglucose positron-emission tomography (FDG-PET) applications in oncology include the differential diagnosis of chest masses and single pulmonary nodules. However, FDG is not tumor-specific; rather, it also accumulates in inflammatory processes. This study was performed to identify image parameters that would improve the specificity of PET. METHODS: Twenty-six patients who had benign and malignant lung lesions were examined retrospectively. Positron-emission tomography data were acquired in dynamic scanning mode after intravenous bolus of 250-402 MBq of FDG. Standardized uptake values (SUVs) were calculated and Patlak analyses were performed in selected regions of interest in the PET images. Positron-emission tomography results were related to histological diagnosis (N = 49) or clinical follow-up (N = 3). RESULTS: The specificity and sensitivity of the original PET scan reports, which was based on visual image interpretation and loosely applied SUVs, was 100% and 73%, respectively. Using the SUVs with a cut-off value of 3.8 and Kpat value with a cut-off at 0.025 min-1 improved the specificity to 81% and 85%. CONCLUSION: FDG-PET image interpretation can be facilitated by using SUV information or the accumulation rate of the radiotracer (Patlak). With additional validation, this method could have a significant cost-effective impact on the medical/surgical management of chest masses.
Asunto(s)
Desoxiglucosa/análogos & derivados , Radioisótopos de Flúor , Enfermedades Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/diagnóstico por imagen , Radiofármacos , Tomografía Computarizada de Emisión , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Análisis Costo-Beneficio , Desoxiglucosa/administración & dosificación , Desoxiglucosa/farmacocinética , Diagnóstico Diferencial , Femenino , Radioisótopos de Flúor/administración & dosificación , Radioisótopos de Flúor/farmacocinética , Fluorodesoxiglucosa F18 , Estudios de Seguimiento , Humanos , Procesamiento de Imagen Asistido por Computador , Inyecciones Intravenosas , Enfermedades Pulmonares/metabolismo , Enfermedades Pulmonares/patología , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Radiofármacos/administración & dosificación , Radiofármacos/farmacocinética , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y Especificidad , Nódulo Pulmonar Solitario/diagnóstico por imagen , Nódulo Pulmonar Solitario/metabolismo , Nódulo Pulmonar Solitario/patología , Tomografía Computarizada de Emisión/economía , Tomografía Computarizada por Rayos XRESUMEN
UNLABELLED: We investigated the use of [18F]fluoro-2-deoxyglucose (FDG) PET scanning for assessment of skeletal muscle viability in patients with peripheral vascular disease and in patients following free-flap skeletal muscle transfer for closure of open wounds. METHODS: We obtained 32 FDG-PET scans from 30 patients, either at the time of admission for peripheral vascular disease (n = 16) or between 1 and 15 days after surgery for skeletal muscle transfer (n = 16). Ratios between injured and contralateral limb FDG tracer activity uptake were correlated with clinical outcome at 1 mo to 3 yr follow-up. RESULTS: Viable muscle uptake ratios ranged from 0.47 to 7.88 (mean: 2.26 +/- 1.81; n = 26), while nonviable muscle uptake ratios ranged from 0.12 to 0.46 (mean: 0.27 +/- 0.12; n = 6; p < 0.02). After skeletal muscle transfer, two patients with viable tissue, as documented by PET, required amputation due to osteomyelitis, and one patient with peripheral vascular disease who showed viable tissue by PET required amputation 3 mo after the PET scan because of recurrent ulcers. CONCLUSION: FDG-PET scanning can determine skeletal muscle viability in patients with peripheral vascular disease and in patients following free-flap transfer.
Asunto(s)
Músculo Esquelético/diagnóstico por imagen , Enfermedades Vasculares Periféricas/diagnóstico por imagen , Colgajos Quirúrgicos , Tomografía Computarizada de Emisión , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Desoxiglucosa/análogos & derivados , Femenino , Fluorodesoxiglucosa F18 , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Colgajos Quirúrgicos/fisiología , Supervivencia TisularRESUMEN
Radiographic imaging techniques have proved to be of limited value in characterizing chest masses. Likewise, scintigraphic techniques with tumor-seeking single photon emitting agents have shown marginal practical benefit. In contrast, high resolution PET with [F-18]-2-fluoro-2-D-deoxyglucose (FDG) offers a unique opportunity to distinguish benign from malignant processes by determining metabolic characteristics. PET scan results, including graphical analysis of tumor transfer constants (Patlak plot) in 21 patients with primary lung cancer, were compared to clinical outcome (histologic proof or clinical follow-up of longer than 1 year) in 54 patients who had chest masses identified by CT and/or plain film. The patients were categorized into three groups. The first group (N = 23) had primary, unknown, lung masses. Differentiation of benign from malignant tumors by PET had a sensitivity of 100% and a specificity of 67%. The second group (N = 13) had proven lung carcinoma or lymphoma and post-therapy PET scanning for recurrent tumor. In this setting, PET had a sensitivity of 83% and a specificity of 80%. The third group (N = 18) had extrathoracic malignancies and suspected pulmonary metastases. Metastatic lesions were identified with a sensitivity of 87% and specificity of 83%. Glucose uptake by normal tissue is variable and inflammatory/infectious processes can have high FDG uptake and overlap with the glucose uptake of malignant tissue. FDG PET is useful in characterizing chest tumors based on the level of their metabolic activity. Malignant tissue has a high glucose uptake. Elevated FDG uptake by an active inflammatory process may produce overlapping results.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Desoxiglucosa/análogos & derivados , Radioisótopos de Flúor , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Torácicas/diagnóstico por imagen , Tomografía Computarizada de Emisión , Diagnóstico Diferencial , Fluorodesoxiglucosa F18 , Humanos , Recurrencia Local de Neoplasia/radioterapia , Estudios Retrospectivos , Sensibilidad y Especificidad , Neoplasias Torácicas/secundario , Tomografía Computarizada por Rayos XRESUMEN
We describe herein a case of esophageal cancer in which both primary and metastatic lymph node foci were successfully imaged with whole-body positron emission tomography (PET) scanning. A 75-year-old woman with biopsy-proven squamous cell carcinoma of the esophagus underwent whole-body PET scanning for staging evaluation. The patient was injected with 373.7 MBq [18F]-2-fluoro-2-D-deoxyglucose (FDG), and 60 min later, scanning was performed from the neck to the pelvis. The whole-body images showed intense FDG uptake in the primary lesion and multiple focal areas of increased FDG uptake in the mediastinum and abdomen, which corresponded to the lymph node foci confirmed by computed tomography (CT) scan. To our knowledge, this is the first report of whole-body PET scanning being applied in the imaging of esophageal cancer.
Asunto(s)
Carcinoma de Células Escamosas/diagnóstico por imagen , Neoplasias Esofágicas/diagnóstico por imagen , Tomografía Computarizada de Emisión/métodos , Anciano , Desoxiglucosa/análogos & derivados , Femenino , Radioisótopos de Flúor , Fluorodesoxiglucosa F18 , Humanos , Metástasis Linfática/diagnóstico por imagen , Estadificación de Neoplasias/métodos , Tomografía Computarizada por Rayos XRESUMEN
This first known positron emission tomography report on metabolic changes in acute herpes simplex virus (HSV-1) encephalitis demonstrates focal hypermetabolism in areas of cerebral cortex adjacent to actively inflamed hippocampus acutely infected with HSV-1. When neuropsychiatric symptoms recurred in a previously healthy 61-year-old patient 1 month after recovering from acute HSV-1 encephalitis, repeat positron emission tomography with fluorodeoxyglucose was helpful in ruling out recurrent active infection by showing marked hypometabolism throughout the previously infected temporal lobe.
Asunto(s)
Encéfalo/metabolismo , Encefalitis/diagnóstico por imagen , Herpes Simple/diagnóstico por imagen , Tomografía Computarizada de Emisión , Enfermedad Aguda , Encefalitis/metabolismo , Encefalitis/microbiología , Femenino , Herpes Simple/metabolismo , Humanos , Persona de Mediana EdadRESUMEN
The potential of positron emission tomography (PET) to distinguish benign from malignant ovarian tissue was evaluated by comparing the results of F-18 fluoro-2-D-deoxyglucose (F-18-FDG) PET scans with computed tomography and surgical findings. If sufficiently sensitive, this method might play a role in localizing metabolically active tumor sites for diagnosis, staging, and follow-up of ovarian cancer. Fifty-one patients had imaging studies prior to laparotomy for suspected ovarian cancer. PET scans were done with an ECAT 931-08-12 or ECAT EXACT (Model 921, Siemens/CTI, Knoxville, TN) after iv injection of 185-370 MBq of F-18-FDG. (ECAT is a trade name for "emission computerized axial tomograph.") Data were acquired in dynamic scanning mode and time activity curves (TACs) were evaluated in multiple regions of interest identified by visual interpretation of the PET scans. Scan interpretation, standardized uptake values, and TAC profiles were related to surgical and histological findings. The results of this pilot study show good correlation between PET and histological findings. The positive predictive value of PET for ovarian cancer was 86% and, perhaps more important, the negative predictive value was 76%. This early work indicates that PET may be useful in the management of patients with ovarian neoplasms by identifying occult foci of metabolically active tumor that do not appear on morphological studies.